There are currently 1380 clinical trials in Atlanta, Georgia looking for participants to engage in research studies. Trials are conducted at various facilities, including Emory University, Emory University Hospital, Children's Healthcare of Atlanta and Emory University Hospital/Winship Cancer Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer
NCT04725994
Recruiting
This is an open-label, Phase 1b study to evaluate the safety and tolerability of IDX-1197 and determine the MTD and RP2D in combination with XELOX or irinotecan in patients with advanced gastric cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/07/2022
Locations: Emory University Winship Cancer Institute, Atlanta, Georgia
Conditions: Gastric Cancer
Register for Updates
Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months
NCT04909021
Recruiting
This study evaluates an investigational vaccine that is designed to protect humans against infection with respiratory syncytial virus (RSV) and is administered as a nasal spray. Specifically, the study analyzes the safety of, and the immune response to, the vaccine when administered to healthy children between the ages of 6 and 24 months who are seronegative to RSV.
Gender:
All
Ages:
Between 6 months and 36 months
Trial Updated:
08/01/2022
Locations: The Emory Children's Center, Atlanta, Georgia
Conditions: Respiratory Syncytial Virus (RSV)
Register for Updates
A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT04901936
Recruiting
The purpose of this study is to evaluate the safety, effectiveness, and biological activity (how the investigational medication is processed by the body) of pegcetacoplan in 12-17 year-olds (adolescents) who have paroxysmal nocturnal hemoglobinuria (PNH).
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
07/18/2022
Locations: Children's Hospital of Atlanta, Atlanta, Georgia
Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Hemoglobinuria
Register for Updates
Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy
NCT03394365
Recruiting
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab and rituximab plus chemotherapy or (2) allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.
Gender:
All
Ages:
All
Trial Updated:
06/23/2022
Locations: Children's Healthcare of Atlanta at Egleston (Pediatrics), Atlanta, Georgia +1 locations
Conditions: Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications
Register for Updates
Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response
NCT02498951
Recruiting
This randomized phase II trial studies how well obinutuzumab works as maintenance treatment in patients with central nervous system lymphoma who have achieved the disappearance of all signs of cancer in response to treatment (complete response) or a decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment (partial response). Immunotherapy with obinutuzumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to gro... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/09/2022
Locations: Piedmont Hospital, Atlanta, Georgia
Conditions: Central Nervous System B-Cell Non-Hodgkin Lymphoma
Register for Updates
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
NCT02847559
Recruiting
The purpose of this research study is to determine the effects bevacizumab (the study drug) combined with Optune (the study device) tumor treatment field therapy has on meningiomas. Bevacizumab is considered investigational because the US Food and Drug Administration (FDA) has not approved its use for the treatment of meningiomas. The study drug is a medication that blocks the growth of new blood vessels. It is thought that the study drug may interfere with the growth of new blood vessels and th... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/25/2022
Locations: Piedmont Healthcare, Atlanta, Georgia
Conditions: Anaplastic (Malignant) Meningioma, Atypical Meningioma, Grade II Meningioma, Grade III Meningioma, Recurrent Meningioma, Supratentorial Meningioma
Register for Updates
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
NCT04857359
Recruiting
This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day). The primary efficacy assessment will be based on the Unified Dyskinesia Rating Scale (UDysRS). Patients who complete the 12-week blinded treatment period may have the option to roll into an open-label safety extension study for an additional 12-month treatment period.
Gender:
All
Ages:
Between 30 years and 85 years
Trial Updated:
05/18/2022
Locations: Emory University, Atlanta, Georgia
Conditions: Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
Register for Updates
The Treatment in Pregnancy for Hepatitis C ("TiP-HepC") Registry
NCT05368974
Recruiting
Clinical interventions to reduce the risk of vertical transmission of hepatitis C virus (HCV) infection from mother to infant are highly limited. Direct-acting antiviral (DAA) medications have demonstrated excellent safety and efficacy in non-pregnant individuals, but there is a lack of data regarding the safety of these medications in pregnant women and the effectiveness of these medications in reducing mother-to-child transmission. Therefore, although HCV screening during pregnancy is now reco... Read More
Gender:
All
Ages:
All
Trial Updated:
05/06/2022
Locations: The Taskforce for Global Health, Atlanta, Georgia
Conditions: Hepatitis C
Register for Updates
Oscillation and Lung Expansion Therapy in Patients With COVID-19
NCT04582214
Recruiting
A Pilot Study of the Use of Oscillation and Lung Expansion (OLE) Therapy in Patients Hospitalized with COVID-19
Gender:
All
Ages:
18 years and above
Trial Updated:
05/04/2022
Locations: Emory University, Atlanta, Georgia
Conditions: COVID-19, Oscillation and Lung Expansion
Register for Updates
SYNCHRONISE: LVO Triage Timing and Outcome Study
NCT04608617
Recruiting
The objective of this study is to evaluate the impact of Viz LVO in hospital systems with non-interventional and interventional (spoke and hub) stroke centers on the timing and outcomes of patients with suspected acute ischemic stroke indicated for mechanical thrombectomy.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/26/2022
Locations: Wellstar Neurosurgery, Atlanta, Georgia
Conditions: Stroke, Ischemic
Register for Updates
Prevent Maternal Mortality Using Mobile Technology
NCT05339867
Recruiting
Black women who reside in a rural area are at highest risk for maternal morbidity and mortality due to a combination of social and structural causes. The postpartum period is the most critical yet most neglected phase for preventing suboptimal or fatal maternal health outcomes. The goal of this project is to use a mobile app to provide personalized support and improve the lives of women during the early postpartum period. The information the study team gathers will help educate women and all who... Read More
Gender:
All
Ages:
Between 18 years and 45 years
Trial Updated:
04/15/2022
Locations: Morehouse School of Medicine, Atlanta, Georgia +1 locations
Conditions: Post-Partum
Register for Updates
Study to Evaluate Effects of INL1 in Patients With Heart Failure and Reduced Ejection Fraction
NCT03875183
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled, dose-response trial in patients with chronic stable Heart Failure (HF) and reduced Left Ventricular Ejection Fraction (LVEF) to evaluate the efficacy and safety of three INL1 doses compared with placebo. Patients will be treated for approximately 12 weeks with one of three INL1 doses: 50 mg, 150 mg, 300 mg, or, placebo capsules, taken twice daily (BID).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/28/2022
Locations: Grady Clinical Research Center, Atlanta, Georgia
Conditions: Heart Failure, Reduced Ejection Fraction
Register for Updates